
Sign up to save your podcasts
Or


With Raja Ezman Faridz Bin Raja Shariff, Universiti Teknologi MARA, Selangor - Malaysia, and Kevin Damman, University Medical Centre Groningen - The Netherlands
In this episode of the HFA Cardiotalk podcast, Ezman Shariff interviewed Kevin Damman – a key opinion leader in the field of cardiorenal interactions, to better understand the role natriuresis plays in the acute heart failure and what we have learnt from trials like PUSH-AHF and ENACT-HF, and the future direction of clinical trials in this field.
This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.
With Jozine ter Maaten, University Medical Center Groningen, Groningen - the Netherlands, Marta Cobo Marcos, Hospital Puerta de Hierro, Madrid - Spain, Mateusz Sokolski, Wroclaw Medical University, Wroclaw, Poland, Aferdita Spahillari, Duke University Hospital, Durham, NC - USA, Laura Cohen, Massachusets General Hospital, Boston, MA - USA, Antonio Cannata, King's College London, London - United Kingdom & Varun Sundaram, Case Western Reserve University, Cleveland, OH, USA
This podcast discusses the results of four late-breaking clinical trials presented at the Heart Failure Congress 2024 in Lisbon, Portugal. First, Dr Cobo Marcos shares the results of the SALT-HF study, a randomised trial investigating the addition of hypertonic saline to diuretics in patients with worsening heart failure. Second, Dr Spahillari and Dr Cohen discuss the main findings and echo substudy of the TEAM-HF trial. Thirdly, Dr Sundaram gives us an insight into the results of the PRAISE-HFpEF trial. The podcast concludes with a brief discussion of some of the HFA Young highlights from the congress.
This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.
With Jozine M. ter Maaten, University Medical Centre Groningen, Groningen - Netherlands, Bart A. Mulder, 2022-2024, University Medical Centre Groningen, Groningen - Netherlands & Giuseppe Boriani, Polyclinic Modena University Hospital, Modena -Italy.
Atrial fibrillation and heart failure often co-exist and influence each other. Treatment of AF specifically in the setting of heart failure can be challenging. Recently, new data emerged regarding the potential role of AF ablation in heart failure patients. In this podcast we discuss these in a special episode with a strong representation also from the EHRA Young highlighting the importance of interdisciplinary decision making in these patients.
Recommended readings from this episode:
CASTLE HTx
CASTLE AF
CABANA results in heart failure patients
This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.
With Cornelia Margineanu, Bucharest - Romania & Thomas Felix Luscher, London - UK
A brief description of the discussion, which I have provided below: "In this episode, Dr. Cornelia Margineanu interviews Professor Thomas F. Lüscher on Education and professional development of the future generation of heart failure specialists, covering the entire pathway for young physicians, from training and having the right mentors to future trajectories.
"This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor."
With Mateusz Sokolski, Wroclaw Medical University, Wroclaw - Poland & Amina Rakisheva, Scientific Research Institute of Cardiology and Internal Diseases, Almaty - Kazakhstan.
Might heart failure be reversible or does it go only into remission in some cases? During this podcast, we discuss these issues, exploring the possibility of reversing heart failure and ending with regenerative medicine.
"This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor."
With Alberto Esteban-Fernández. Severo Ochoa University Hospital, Madrid - Spain & John McMurray. BHF Glasgow Cardiovascular Research Centre, Glasgow - UK.
We discuss the implementation of 2021 HF guidelines, the possibility of implementing foundational therapy in clinical practice, and difficulties and barriers. Also, we discuss future heart failure treatments in the coming years. Access the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
"This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor."
With Antonio Cannata, King's College London - UK and Folkert Asselbergs, Amsterdam University Medical Centre - Netherlands.
In this episode of HFA CardioTalk Antonio Cannata interviews one of the pioneer in digital medicine and artificial intelligence in cardiovascular medicine, Prof Folkert Asselbergs. Several interesting insights were discussed on the present role of AI in Heart Failure and what the future holds.
"This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor."
With Henrike Arfsten,Medical University of Vienna - Austria & Antoni Bayes-Genis, Heart Institute, University Hospital Germans Trias and Pujol de Badalona - Spain
In this episode of HFA CardioTalk, Henrike Arfsten interviews Antoni Bayes-Genis on circulating biomarkers in heart failure. They focus in particular on natriuretic peptides and discuss the benefits of biomarkers assessment and their fundamental role in heart failure diagnosis and disease progression.
NEW! If you want to know more on this topic, access some recommended readings from the speakers:
- Bayes-Genis A, et al.; Eur J Heart Fail. 2023 Sep 15
- Mueller C, et al.; Eur J Heart Fail. 2019 Jun;21(6):715-731.
- Bayes-Genis A, et al.; Eur J Heart Fail. 2021:23,1432–1436.
- Huelsmann M, et al.; J Am Coll Cardiol. 2013 Oct 8;62(15):1365-72
- Tsutsui H, et al; Eur J Heart Fail. 2023 May;25(5):616-631.
With Chris Kapelios, Onassis Cardiac Surgery Center, Athens - Greece & Gianluigi Savarese, Karolinska University Hospital, Stockholm - Sweden.
This HFA CardioTalk podcast episode addresses Clinical inertia and optimization of heart failure therapy.
The data we have on use of HF medications come from registries and may not be generalizable to unselected, real-world populations. The proportion of HFrEF patients treated with optimal medical therapy differs considerably among registries (between 70% to >90% for a beta-blocker, 60% to >90% for RASi, 15-45% for ARNI, 30-60% for MRA). It is well documented that optimal HFrEF treatment leads to better quality of life, and reduction in mortality, HF hospitalizations and healthcare costs. Clinical inertia is the lack of treatment intensification in patients not on optimized therapy. Its manifestations may differ from country to country, but it is always present, irrespective of whether the approach to HF medication initiation is sequential or in parallel. Increase of awareness, collaboration of all healthcare professionals, and use of checklists and digital tools are among the measures we can apply to tackle clinical inertia.
With Antonio Cannata, King's College London, London - UK & Stuart Pocock, London School of Hygiene & Tropical Medicine, London - UK.
In this episode of HFA CardioTalk, Antonio Cannata interviews Stuart Pocock on how to understand randomised clinical trials. From the use of observational data to the key points in critically interpreting the results. Don't forget: a p value is no substitute for a brain.
From the publisher's feed

163 Listeners

40 Listeners

893 Listeners

31 Listeners

135 Listeners

1,197 Listeners

184 Listeners

64 Listeners

17 Listeners

438 Listeners

32 Listeners

4 Listeners

8 Listeners

0 Listeners